...
首页> 外文期刊>Washington Drug Letter >Byetta Indication Expanded, Labeling Gets New Warning
【24h】

Byetta Indication Expanded, Labeling Gets New Warning

机译:Byetta指示扩展,标签收到新警告

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Amylin Pharmaceuticals and Eli Lilly's in-jectable Type 2 diabetes drug Byetta has received FDA approval for use as a standalone treatment, but the label also has been updated with warnings about pancreatitis and possible kidney function impairment.rnThe agency's action expands the drug's indication - Byetta (exenatide) had been approved to treat patients who also take other common diabetes medications but do not achieve adequate glycemic control. As a monotherapy, Byetta still must be combined with diet and exercise to improve glycemic control in adults with Type 2 diabetes, Amylin and Lilly say in a statement last week.
机译:Amylin Pharmaceuticals和Eli Lilly的2型可注射性糖尿病药物Byetta已获得FDA批准可作为独立治疗药物使用,但标签上还更新了有关胰腺炎和可能的肾功能损害的警告。rn该机构的行动扩大了该药物的适应症-Byetta (艾塞那肽)已被批准用于治疗也服用其他常见糖尿病药物但未实现充分血糖控制的患者。 Amylin和礼来在上周的一份声明中说,作为一种单一疗法,Byetta仍必须与饮食和运动相结合,以改善2型糖尿病成年人的血糖控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号